Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan

Valsecchi AA, Pisegna S, Antonuzzo A, et al.

In this study, a panel of 29 experts voted on 40 statements to provide a foundational framework for clinical decision-making related to safety, dosing regimens, and patient management for sacituzumab govitecan. These findings highlight the need for collaborative input for developing practice guidelines.